Preview Mode Links will not work in preview mode

Apr 21, 2021

Proceedings from part 4 of a 4-part webinar series. Featuring perspectives from Drs Paul M Barr, Matthew S Davids and Kerry Rogers, including the following topics:

  • Introduction (0:00)
  • Available and emerging data with Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia (CLL) (0:53)
  • Role of Bcl-2 inhibitors for CLL (26:46)
  • Novel strategies under investigation for CLL — U2 regimen (umbralisib/ublituximab) and CAR (chimeric antigen receptor) T-cell therapy (50:17)

CME information and select publications